



US2.AI

# 2024 Year in Review

# Us2.v2 FDA Clearance



FDA has granted 510(k) clearance for the Us2.v2 software, featuring **45 automated echo parameters** including **Strain analysis, Aortic stenosis measurements, comprehensive quantitative analysis of cardiac structure and function**, and essential measurements used in current guidelines for the **detection of conditions** such as **cardiac amyloidosis** and **heart failure with preserved ejection fraction**.

“By offering advanced capabilities that significantly enhance both precision and efficiency of echocardiographic analysis, this innovation dramatically reduces analysis time thereby speeding up clinical workflow....it also ensures high-quality patient care with the integration of international guidelines that aligns with the latest clinical standards”

**Madhav Swaminathan, MD**

*Professor of Anesthesiology at Wake Forest University School of Medicine  
Past president of the American Society of Echocardiography (ASE)*



Leading with the Science: Us2.ai's 2024 Scientific Achievements



# More than **35** Research Publications and Abstracts

Cardiac Amyloidosis

*Late Breaker at EuroEcho Imaging 2024*

Heart Failure

Mitral Regurgitation

Aortic Stenosis

Time Efficiency

Benefits of AI-Echo

*Late Breaker at AHA 2024*


AI in Electronic Health Record Surveillance

POCUS-AI enhanced novice echo screening & Community-based screening

Patient Attitudes towards AI-Echo

In the Spotlight

# Us2.ai in the Press



Rheumatic Heart Disease Screening using Us2.ai - The Washington Post



Everton in the Community

Forging Connections

# Key Partnerships in 2024




In 2024, Us2.ai continued to expand its collaborations, showcasing AI's transformative potential to democratize echocardiography and unlock new clinical pathways.

## Symphony



This is an international prospective, multicentre, unblinded, randomised-controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients.

## Beat to Treat



Through the **BEAT HF public awareness and Heart Health campaign**, nearly 6,000 individuals across the UK were tested for heart failure. Reducing diagnosis time from six months to just 60 minutes.

## Collaborations

Us2.ai is also honoured to be collaborating with renowned research centres for scientific advances in AI-echo, including:



# Clinical Advantages of Us2.ai



The AI-ECHO RCT, a Late Breaking Science presentation at AHA 2024, revealed the significant advantages of integrating Us2.ai into clinical workflows. The study identified five key benefits:



Increase in number of daily examinations



Reduction in echo examination time



**Richer Clinical Data:** AI analysis of additional parameters provided clinicians with more comprehensive data for better clinical decision-making.




Reduced mental and physical fatigue of sonographers



Improved image quality

Kagiyama N. Artificial intelligence-based automated echocardiographic measurements and the workflow of sonographers: randomized crossover trial (AI-Echo RCT). Presented at: AHA 2024. November 16, 2024. Chicago, IL.

# Implementation Successes & Growing Client Base



# Upholding Quality, Security Standards, & Achieving Global Regulatory Clearances



## Regulatory Clearances

Registered and marketed in 31 countries



## Cyber Security



Us2.ai maintained our security posture under the rigorous frameworks of ISO 27001:2023, ISO 27017:2015, ISO 27018:2019, SOC II Type 2 and UK Cyber Essentials Plus

Compliant to the HIPAA and GDPR regulations

Certified under the new Singapore CSA Cyber Essentials framework

## Quality



Us2.ai is dedicated to maintaining the highest standards in quality and data security, with no adverse events, serious incidents, field service corrective actions, or cybersecurity incidents reported.



# Want to **learn more?**



**Visit us at Us2.ai:**

- News: <https://us2.ai/news/>
- Publications: <https://us2.ai/publications>



**Contact us for a demo:**

- <https://us2.ai/contact-us/>

**Let's continue to revolutionize cardiovascular care together!**